HANK & LIN'S GROUP

The past is prologue and the future is scintillating

177Lu-P15-073

  • [177Lu]Lu-P15-073 is a novel bisphosphonate-based radioligand therapy (RLT) agent developed for targeted treatment of bone metastases. This radiopharmaceutical combines the high specificity of bisphosphonates for bone tissue with the therapeutic potential of the radioisotope Lutetium-177 ([177Lu]), a beta-emitting radionuclide used in targeted radionuclide therapy.
  • The bisphosphonate moiety in P15-073 selectively binds to the hydroxyapatite in bone, particularly in areas of increased osteoblastic activity such as bone metastases. When radiolabeled with [177Lu], this compound enables targeted radiation delivery directly to metastatic bone sites, minimizing damage to surrounding healthy tissues.


  1. Zhao, R., Lv, J., Li, M.et al.First-in-human study of dosimetry, safety and efficacy for [177Lu]Lu-P15-073: a novel bisphosphonate-based radioligand therapy (RLT) agent for bone metastases. Eur J Nucl Med Mol Imaging(2024). https://doi.org/10.1007/s00259-024-06942-0
  2. Wenbin Jin, Ruiyue Zhao, Ran Wang, et al. Theranostic Agent Targeting Bone Metastasis: A Novel [68Ga]Ga/[177Lu]Lu-DOTA-HBED-bisphosphonate. Journal of Medicinal Chemistry2024,67(6):4793-4803. https://doi.org/10.1021/acs.jmedchem.3c02372









3. Jin, W., Wang, R., Zhao, R., Choi, S., Ploessl, K., Alexoff, D., Zhu, L. and Kung, H., 2024. Theranostic Agent Targeting Bone Metastasis: A Novel [68Ga] Ga/[177Lu] Lu-DOTA-HBED-bisphosphonate.Journal of Nuclear MedicineJune 2024,65(supplement 2)241097;

4. Zhao, Ruiyue, Jie Lv, Siran Xu, WenBin Jin, David Alexoff, Karl Ploessl, Lin Zhu, Hank Kung, and Xinlu Wang. "Evaluation safety, dosimetry and efficacy of [177Lu] Lu-P15-073 for therapy of bone metastases."Journal of Nuclear MedicineJune 2024,65(supplement 2)241395;